ULTRAGENYX PHARMACEUTICAL INC. Investments, Fair Value Disclosure
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Investments, Fair Value Disclosure of $397.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:InvestmentsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Investments, Fair Value Disclosure $397.00M.
- 2026-03-31: Investments, Fair Value Disclosure $477.00K.
- 2025-12-31: Investments, Fair Value Disclosure $687.00M.
- 2025-09-30: Investments, Fair Value Disclosure $390.19M.
| Period end | Investments, Fair Value Disclosure | Investments, Fair Value Disclosure as first filed |
|---|---|---|
| 2026-06-30 | $397.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $477.00K 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $687.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $390.19M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $498.92M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $528.54M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $713.00M 10-K · filed 2026-02-18 | $713.20M 10-K · filed 2025-02-19 |
| 2024-09-30 | $793.72M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $849.32M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $556.75M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $749.24M 10-Q · filed 2024-11-06 | |
| 2023-09-30 | $507.02M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $605.17M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $701.00M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $749.24M 10-K · filed 2025-02-19 | $884.02M 10-K · filed 2023-02-17 |
| 2022-09-30 | $990.19M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $693.90M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $817.85M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $1.00B 10-K · filed 2023-02-17 | |
| 2021-09-30 | $1.00B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $1.04B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.15B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.33B 10-K · filed 2022-02-15 | |
| 2020-09-30 | $875.50M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $929.07M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $698.46M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $768.92M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $529.21M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $628.51M 10-Q · filed 2019-08-02 | |
| 2018-12-31 | $434.74M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |